Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Tuesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

Some opportunities aren't for everyone. Peptinovo's PALM™ platform represents a rare convergence: breakthrough science, proven leadership, and a narrow window before institutional capital floods in.

While major pharmaceutical players circle from the sidelines, waiting for human trial data to de-risk their entry, a select group of early investors has the chance to own the entire platform—not just one drug candidate, but a revolutionary delivery system that works across multiple blockbuster chemotherapies.

This isn't your typical biotech gamble. Founder Ren Homan already sold his previous company, AlphaCore, to AstraZeneca. His team has collectively launched 10 biotech startups, with 4 of them acquired by major corporations. They've done this before. They know the playbook. And they're inviting you to join them before the institutional investors arrive with their term sheets.

The PALM™ platform exploits cancer cells' own growth mechanisms—using HDL mimics to deliver chemotherapy like a Trojan horse. Animal studies show equivalent or superior tumor suppression with virtually no nerve damage, reduced nausea, and minimal side effects that plague current treatments. Five different PALM™ drug combinations are already developed, positioning early backers to benefit from multiple licensing deals and acquisition opportunities.

Here's what separates you from those who wait: Early investors capture the full value inflection. When Peptinovo's first-in-human data arrives in 6-12 months, those waiting on the sidelines will pay substantially more for substantially less. They'll miss the platform ownership that comes with early commitment.

The beachhead market alone—ovarian cancer—is worth $145 million in the U.S. The global paclitaxel market exceeds $7 billion. But PALM™'s actual value lies in its platform potential: a $124 billion oncology market where antibody drug conjugates (ADCs) have already driven over $60 billion in acquisitions despite their toxicity challenges.

You're not just investing in better cancer treatment. You're joining founders who've successfully exited before, positioning yourself ahead of institutional capital, and gaining ownership of a platform that could generate multiple revenue streams through licensing deals—potentially before regulatory approval even arrives.

The question isn't whether PALM™ will succeed. It's whether you'll be inside when it does.

To access Peptinovo and review all required disclosures, risks, and offering materials, visit the company’s designated offering page on the funding portal.

Final Reminder: This article provides information and perspective, not investment advice. All investments involve risk. Readers interested in Peptinovo Biopharma, Inc. should conduct thorough due diligence, review all official offering documents, understand the specific terms and risks, and consider consulting with financial advisors before making any investment decisions.

Investing in startups is speculative, involves a high degree of risk, and investors should be able to bear the loss of their entire investment. All investments must be made through the registered funding portal.

This newsletter is for informational purposes only and does not constitute investment advice or a solicitation to invest. Invst Guru is not affiliated with Peptinovo Biopharma, Inc, Silicon Praire, or any broker-dealer. Any investment in private or early-stage companies involves risk, including the potential loss of your entire investment. All investments in Peptinovo Biopharma, Inc must be made through its official Regulation Crowdfunding (Reg CF) campaign page on Silicon Praire. No investment terms are included in this newsletter. For full offering details, risk factors, and disclosures, please review the company’s official Form C filing and offering page.